BioSpace News Archive

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

The Canadian Cancer Trials Group (CCTG) today announced the commencement of a new sub-study evaluating CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 (PLK4), in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close.

Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29 th , 2020

BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated January 17, 2020 (the “Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”).

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received a request for additional information from the U.S. Food and Drug Administration (the “FDA” or “Agency”) related to the Company’s request for de novo classification and clearance of the Portable Neuromodulation Stimulator (PoNS™) device as a potential treatment for gait de

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have a poster at

National Health Investors, Inc. provided a business update regarding its monthly contractual rent collections and average occupancy from its three largest senior housing operators.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to announce third quarter 2020 financial results and discuss recent business updates. The webcast can be accessed on the inve

JACKSON CENTER, PA / ACCESSWIRE / October 19, 2020 / Halberd Corporation (OTC PINK: HALB ) today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. Felder, MD. Halberd and ASU have begun the process of filing the first of multiple planned join